Dividendos de Jubilant Pharmova
Dividendo controles de criterios 3/6
Jubilant Pharmova es una empresa que paga dividendos con una rentabilidad actual de 0.74%.
Información clave
0.7%
Rentabilidad por dividendo
-130%
Ratio de pago
| Rentabilidad media de la industria | 0.8% |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | n/a |
| Beneficios por acción | ₹2.38 |
| Rentabilidad por dividendo prevista a 3 años | 0.7% |
Últimas actualizaciones de dividendos
Recent updates
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14
Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08
Shareholders Are Thrilled That The Jubilant Life Sciences (NSE:JUBILANT) Share Price Increased 217%
Jan 11Does Jubilant Life Sciences' (NSE:JUBILANT) CEO Salary Compare Well With Industry Peers?
Dec 31Read This Before Selling Jubilant Life Sciences Limited (NSE:JUBILANT) Shares
Dec 20Has Jubilant Life Sciences Limited's (NSE:JUBILANT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 08We Think Jubilant Life Sciences (NSE:JUBILANT) Can Stay On Top Of Its Debt
Nov 27What Kind Of Investors Own Most Of Jubilant Life Sciences Limited (NSE:JUBILANT)?
Nov 17Jubilant Life Sciences Limited Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next
Nov 06If You Like EPS Growth Then Check Out Jubilant Life Sciences (NSE:JUBILANT) Before It's Too Late
Oct 27Estimating The Fair Value Of Jubilant Life Sciences Limited (NSE:JUBILANT)
Oct 15Does Jubilant Life Sciences' (NSE:JUBILANT) Share Price Gain of 96% Match Its Business Performance?
Oct 03Trade Alert: The Independent Non-Executive Director Of Jubilant Life Sciences Limited (NSE:JUBILANT), Arun Seth, Has Just Spent ₹1.1m Buying 233% More Shares
Sep 21How Much is Jubilant Life Sciences' (NSE:JUBILANT) CEO Getting Paid?
Sep 20Jubilant Life Sciences Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Sep 08Should You Take Comfort From Insider Transactions At Jubilant Life Sciences Limited (NSE:JUBILANT)?
Sep 03Jubilant Life Sciences Limited's (NSE:JUBILANT) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Aug 24Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: Los dividendos por acción de JUBLPHARMA se han mantenido estables en los últimos 10 años.
Dividendo creciente: El pago de dividendos de JUBLPHARMA ha aumentado en los últimos 10 años.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de Jubilant Pharmova vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (JUBLPHARMA) | 0.7% |
| Suelo de mercado 25% (IN) | 0.3% |
| Techo de mercado 25% (IN) | 1.2% |
| Media de la industria (Pharmaceuticals) | 0.8% |
| Previsión de analistas en 3 años (JUBLPHARMA) | 0.7% |
Dividendo destacado: El dividendo de JUBLPHARMA(0.74%) es más alto que el 25% inferior de los pagadores de dividendos del mercado Indian (0.27%).
Alto dividendo: El (0.74%) del dividendo de JUBLPHARMA es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado Indian (1.19%).
Pago de beneficios a los accionistas
Cobertura de los beneficios: JUBLPHARMA paga dividendo, pero la empresa no es rentable.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: Con su elevado ratio de pago en efectivo (597.2%), los pagos de dividendos de JUBLPHARMA no están bien cubiertos por los flujos de caja.